Holen Sie sich die Stockscreener-App
2.33
0.87%
0.02
Schlusskurs vom Vortag:
$2.31
Offen:
$2.3
24-Stunden-Volumen:
2.80M
Relative Volume:
0.37
Marktkapitalisierung:
$419.60M
Einnahmen:
$850.00K
Nettoeinkommen (Verlust:
$-68.17M
KGV:
-5.6608
EPS:
-0.4116
Netto-Cashflow:
$-53.29M
1W Leistung:
+2.64%
1M Leistung:
+21.35%
6M Leistung:
-56.45%
1J Leistung:
-18.25%
1-Tages-Spanne:
$2.19
$2.36
1-Wochen-Bereich:
$2.15
$2.36
52-Wochen-Spanne:
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Firmenname
Compass Therapeutics Inc
Sektor
Branche
Telefon
617-500-8099
Adresse
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.33 | 419.60M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-13 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-05 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-12-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-02 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Eingeleitet | Guggenheim | Buy |
| 2025-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Eingeleitet | Jefferies | Buy |
| 2023-01-27 | Eingeleitet | Stifel | Buy |
| 2022-05-23 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-03-15 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-01-19 | Eingeleitet | B. Riley Securities | Buy |
| 2021-12-22 | Eingeleitet | Raymond James | Outperform |
| 2021-12-20 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-15 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Driven by Disciplined SpendingHigh Estimate Range - dars.gov.et
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
If You Invested $1,000 in Compass Therapeutics Inc (CMPX) - Stock Titan
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX) - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
Compass Showcases Promising Tovecimig Data, Eyes Commercialization - TipRanks
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement - TradingView
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic - The National Law Review
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to earnings forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
$Compass Therapeutics (CMPX.US)$ - Moomoo
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings - Moomoo
Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX) - TradingView
CMPX Forecast — Price Target — Prediction for 2027 - TradingView
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compass Therapeutics Adopts Second Amended and Restated Bylaws - The Globe and Mail
Compass Therapeutics Inc. (CMPX) Institutional Confidence - TradingKey
Compass Therapeutics Inc. (CMPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compass Therapeutics Inc. (CMPX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing - Insider Monkey
Compass Therapeutics Inc. (CMPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
5 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
Compass Therapeutics eyes FDA path after Tovecimig trial win - MSN
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight - The Globe and Mail
Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes - Stock Titan
CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead - TradingView
Compass Therapeutics, Inc. (CMPX) Latest Stock News & Headlines - Yahoo Finance
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win - MarketBeat
CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Citizens reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Nigeria
CMPX: Lead drug tovecimig showed strong efficacy in BTC; key FDA and data milestones expected this year - TradingView
CMPX Stock Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Piper Sandler Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Stifel reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Canada
Number of shareholders of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
CMPX Q1 2026 Earnings: Narrow EPS Beat Drives Positive Stock ReactionTrough Earnings Signal - thelegaladvocate.com
Compass Therapeutics to Participate in Upcoming June Investor Events - Investing News Network
CMPXCompass Therapeutics Inc Latest SEC Filings - Finviz
Finanzdaten der Compass Therapeutics Inc-Aktie (CMPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):